Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects
Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
THOUSAND OAKS, Calif. , May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive...
Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.
LOS ANGELES , May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc ., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures,...
Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.
Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.
Thomas Dittrich Returning to Amgen as CFO
3 Large-Cap Stocks Worth Investigating
2 Cash-Producing Stocks on Our Watchlist and 1 We Turn Down